Situation of the Prescription service

The situation of the joint testing of the Prescription service is compiled on this page. Tabulating starts from joint tests completed on 29 April 2016.

Read more about the requirements for taking part in joint testing on the Kanta Services website:

Situation of the Prescription service

Open all

Abilita Hälsovård / Abilita Oy Ab

Ongoing joint testings

No ongoing joint testings

Table: Abilita Hälsovård / Abilita Oy Ab accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20102016 / 30.12.2016
Functionality for action on behalf of a minor	20072020 / 14.9.2020
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	20122022 / 8.2.2022
The 2022 changes of the Pharmaceutical Database	20022023 / 1.2.2023

Acute / Vitec Acute Oy

Ongoing joint testings

No ongoing joint testings

Table: Acute / Vitec Acute Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20012016 / 30.11.2016
Forward compatibility of the functionality to act on behalf of a minor	- / 17.2.2020
Functionality for action on behalf of a minor	20072021 / 14.9.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	20032022 / 3.2.2022
The 2022 changes of the Pharmaceutical Database	20272022 / 5.10.2022

AssisDent / Entteri Professional Software Oy

Ongoing joint testings

No ongoing joint testings

Table: AssisDent / Entteri Professional Software Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20062016 / 27.12.2016
Forward compatibility of the functionality to act on behalf of a minor	- / 14.9.2020
Functionality for action on behalf of a minor	20062021 / 30.6.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	27.4.2022 / 20162022
The 2022 changes of the Pharmaceutical Database	20052023 / 8.3.2023

DomaCare / Invian Oy

Table: DomaCare / Invian Oy ongoing joint testings
Ongoing joint testings	Registration, return date of pre-test cases	Testing between system supplier and Kela	Testing between client test organisation and Kela	Cross-testing
The 2022 changes of the Pharmaceutical Database	17.11.2022	Ongoing, 21.11.2022	Not tested	Not tested

Table: DomaCare / Invian Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9	20142017 / 14.3.2017
Functionality for action on behalf of a minor	20032021 / 4.5.2021
Refusal to share prescription information	20052021 / 29.6.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	29.4.2022 / 20172022

DynamicHealth / TietoEVRY Oyj

Ongoing joint testings

No ongoing joint testings

Table: DynamicHealth / TietoEVRY Oyj accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20032016 / 30.12.2016
Forward compatibility of the functionality to act on behalf of a minor	- / 12.3.2020
Functionality for action on behalf of a minor	20122020 / 20.11.2020
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	20022022 / 2.2.2022
The 2022 changes of the Pharmaceutical Database	20042023 / 2.2.2023
Prescription's MR and CDA R2 specifications 4.00 and requirement specifications 3.00 (DynamicHealth eResepti Interface)	20112023 / 26.4.2023

Effica / TietoEVRY Oyj

Ongoing joint testings

No ongoing joint testings

Table: Effica / TietoEVRY Oyj accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20032016 / 9.12.2016

Epic / Epic Helsinki Oy

Ongoing joint testings

No ongoing joint testings

Table: Epic / Epic Helsinki Oy accepted joint testing
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.42 and requirement specifications 2.9, Refusal to share prescription information	20022018 / 5.10.2018
Forward compatibility of the functionality to act on behalf of a minor	- / 7.9.2020
Functionality for action on behalf of a minor	2.5.2022 / 20192022
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database (Prescription's HL7 specifications 3.42)	29.4.2022 / 20182022
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database (Prescription's HL7 specifications 3.63)	5.5.2022 / 20212022
The 2022 changes of the Pharmaceutical Database	20032023 / 25.1.2023

ERA / Atostek Oy

Ongoing joint testings

No ongoing joint testings

Table: ERA / Atostek Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20092016 / 29.12.2016
Functionality for action on behalf of a minor	20032020 / 16.3.2020
Functionality for action on behalf of a minor (testing of system changes)	20052020 / 10.8.2020
The 2022 version of the Pharmaceutical Database	20102022 / 11.4.2022
Structured dosage	20112022 / 12.4.2022
FHIR interface to search for identifiers	20082022 / 22.3.2022

ESKO / Esko Systems Oy

Ongoing joint testings

No ongoing joint testings

Table: ESKO / Esko Systems Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20022016 / 9.12.2016
Forward compatibility of the functionality to act on behalf of a minor	- / 7.5.2020
Functionality for action on behalf of a minor	20012022 / 31.1.2022
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	20132022 / 11.4.2022
The 2022 changes of the Pharmaceutical Database	20302022 / 27.10.2022

GFS / CGI Oy

Ongoing joint testings

No ongoing joint testings

Table: GFS / CGI Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	- / 25.11.2016
Forward compatibility of the functionality to act on behalf of a minor	- / 6.2.2020
Functionality for action on behalf of a minor	20082020 / 22.9.2020

Hilkka / FastROI Oy

Ongoing joint testings

No ongoing joint testings

Table: Hilkka / FastROI Oy a joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9	20082016 / 30.12.2016
Refusal to share prescription information	20012018 / 11.1.2018
Forward compatibility of the functionality to act on behalf of a minor	- / 16.4.2020
Functionality for action on behalf of a minor	20022021 / 12.4.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	26.4.2022 / 20152022
The 2022 version of the Pharmaceutical Database	20072023 / 4.4.2023
Structured dosage	20132023 / 11.5.2023

KEJO/ PCC-ryhmittymä

Ongoing joint testings

No ongoing joint testings

Table: KEJO / PCC-ryhmittymä accepted joint testings
Accepted joint testings	Statement number and date
Search and viewing of data concerning prescriptions and dispensations	20142020 / 23.11.2022

Kelain / Kela

Ongoing joint testings

No ongoing joint testings

Table: Kelain / Kela accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9	20042016 / 13.12.2016
Refusal to share prescription information	20202017 / 1.6.2017
Functionality for action on behalf of a minor	20012020 / 14.1.2020
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	20042022 / 3.2.2022
The 2022 changes of the Pharmaceutical Database	20282022 / 13.10.2022
Structured dosage	20292022 / 13.10.2022

Lifecare / TietoEVRY Oyj

Table: Lifecare / TietoEVRY Oyj ongoing joint testings
Ongoing joint testings	Registration, return date of pre-test cases	Testing between system supplier and Kela	Testing between client test organisation and Kela	Cross-testing
Structured dosage	22.12.2022	Not started	Not tested	Not tested

Table: Lifecare / TietoEVRY Oyj accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20192017 / 11.5.2017
Forward compatibility of the functionality to act on behalf of a minor	- / 14.2.2020
Functionality for action on behalf of a minor	20102021 / 18.11.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	20062022 / 23.2.2022
The 2022 version of the Pharmaceutical Database	20062023 / 24.3.2023

MAXX / Receptum Oy

Ongoing joint testings

No ongoing joint testings

Table: MAXX / Receptum Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20122017 / 11.1.2017
Cross-border prescription	20012019 / 30.9.2019
Functionality for action on behalf of a minor	20062020 / 8.9.2020
The 2022 changes of the Pharmaceutical Database	20252022 / 29.4.22
Structured dosage	20262022 / 29.4.22
Code identifying a prescribed medicine at the pharmacy	20082023 / 13.4.2023

Mediatri / Mediconsult Oy

Ongoing joint testings

No ongoing joint testings

Table: Mediatri / Mediconsult Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9	20072016 / 30.12.2016
Refusal to share prescription information	20212017 / 5.6.2017
Forward compatibility of the functionality to act on behalf of a minor	- / 5.5.2020
Functionality for action on behalf of a minor	20042020 / 8.10.2020
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	17.2.2022 / 20072022
The 2022 changes of the Pharmaceutical Database	20322022 / 28.11.2022

Mediatri Saga / Mediconsult Oyj

Table: Mediatri Saga / Mediconsult Oyj ongoing joint testings
Ongoing joint testings	Registration, return date of pre-test cases	Testing between system supplier and Kela	Testing between client test organisation and Kela	Cross-testing
The 2022 version of the Pharmaceutical Database	13.3.2023	Not started	Not tested	Not tested

Table: Mediatri Saga / Mediconsult Oyj accepted joint testings
Accepted joint testings	Statement number and date
Prescription's HL7 specifications 3.63 and functional specification 2.94	20312022 / 4.11.2022

Mediresepti / Mediconsult Oy

Ongoing joint testings

No ongoing joint testings

Table: Mediresepti / Mediconsult Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9	20132016 / 30.12.2016
Refusal to share prescription information	20222017 / 4.12.2017
Forward compatibility of the functionality to act on behalf of a minor	- / 8.5.2020
Functionality for action on behalf of a minor	20132020 / 26.11.2020
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	20092022 / 22.3.2022

Navitas / Elisa Appelsiini Oy

Ongoing joint testings

No ongoing joint testings

Table: Navitas / Elisa Appelsiini Oy accepted joint testings
Accepted joint testings	Statement number and date
Refusal to share prescription information	20182017 / 24.2.2017

Norre / Norre Työterveys Oy

Table: Norre / Norre Työterveys Oy ongoing joint testings
Ongoing joint testings	Registration, return date of pre-test cases	Testing between system supplier and Kela	Testing between client test organisation and Kela	Cross-testing
Prescription's MR and CDA R2 specifications 4.0 and requirement specifications 3.0	25.8.2022	Discontinued	Not started	Not started

Omapd / Pharmadata Oy

Ongoing joint testings

No ongoing joint testings

Table: Omapd / Pharmadata Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 4.0 and requirement specifications 3.0	20012023 / 1.2.2023
Code identifying a prescribed medicine at the pharmacy	20102023 / 26.4.2023

pd3 / Pharmadata Oy

Ongoing joint testings

No ongoing joint testings

Table: pd3 / Pharmadata Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20172017 / 27.1.2017
Cross-border prescription	20022020 / 20.2.2020
Functionality for action on behalf of a minor	20102020 / 24.9.2020
Structured dosage	3.5.2022 / 20242022
The 2022 changes of the Pharmaceutical Database	3.5.2022 / 20232022
Code identifying a prescribed medicine at the pharmacy	20092023 / 26.4.2023

Pegasos OMNI360 Kertomus / CGI Oy

Ongoing joint testings

No ongoing joint testings

Table: Pegasos OMNI360 Kertomus / CGI Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20052016 / 20.12.2016
Forward compatibility of the functionality to act on behalf of a minor	- / 8.4.2020
Functionality for action on behalf of a minor (OMNI360 Kertomus)	20012021 / 21.1.2021
Functionality for action on behalf of a minor	20082021 / 14.9.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database (OMNI360 Kertomus)	20122021 / 18.11.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	20052022 / 24.2.2022
The 2022 changes of the Pharmaceutical Database (OMNI360 Kertomus)	20342022 / 20.12.2022

Sairec / CGI Oy

Table: Sairec / CGI Oy ongoing joint testings
Ongoing joint testings	Registration, return date of pre-test cases	Testing between system supplier and Kela	Testing between client test organisation and Kela	Cross-testing
Prescription's MR and CDA R2 specifications 4.0 and requirement specifications 3.0	20.9.2022	Completed, 24.3.2023	Ongoing, 24.3.2023	Not started

Salix / Pharmadata Oy

Ongoing joint testings

No ongoing joint testings

Table: Salix / Pharmadata Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20162017 / 27.1.2017
Cross-border prescription	20022019 / 10.12.2019
Functionality for action on behalf of a minor	20092020 / 24.9.2020
Structured dosage	20222022 / 3.5.2022
The 2022 changes of the Pharmaceutical Database	20202022 / 3.5.2022
Code identifying a prescribed medicine at the pharmacy	20122023 / 27.4.2023

SoftMedic / CGI Oy

Ongoing joint testings

No ongoing joint testings

Table: SoftMedic / CGI Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	- / 22.11.2016
Forward compatibility of the functionality to act on behalf of a minor	- / 10.9.2020
Functionality for action on behalf of a minor	20092021 / 11.10.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	8.4.2022 / 20142022
The 2022 changes of the Pharmaceutical Database	30.12.2022 / 20352022

Uranus / CGI Oy

Ongoing joint testings

No ongoing joint testings

Table: Uranus / CGI Oy accepted joint testings
Accepted joint testings	Statement number and date
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information	20152017 / 11.1.2017
Forward compatibility of the functionality to act on behalf of a minor	- / 14.1.2020
Functionality for action on behalf of a minor	20042021 / 16.6.2021
Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database	20112021 / 18.11.2021
The 2022 changes of the Pharmaceutical Database	20332022 / 20.12.2022